628-The Cellular Orchestra of CAR T Success in Myeloma

This paper examines a longitudinal single-cell atlas that identifies the biological drivers behind the success or failure of BCMA-targeted CAR T cell therapy in multiple myeloma patients. The research highlights that long-term remission is not determined by cell dose, but rather by specific T cell phenotypes, particularly the presence of cytotoxic CD4+ T cells and memory-biased states. It also redefines cell exhaustion, noting that dysfunctional T cells often show mitochondrial issues and specific markers like TIGIT rather than traditional exhaustion signals. Furthermore, the study identifies soluble BCMA as a potential biomarker for tracking both treatment response and inflammatory toxicities. These findings suggest that future improvements in manufacturing and patient monitoring could lead to more precise and effective immunotherapies. Overall, the text provides a detailed roadmap for optimizing cellular engineering to achieve durable clinical outcomes and better manage side effects.References: Samur M K, Munshi N C. The cellular orchestra of CAR T success[J]. Cancer Cell, 2026.前往小宇宙评论区与主播互动